Financial Performance - XP Inc's client assets, AUM, and AUA reached R$1.9 trillion, a 17% increase year-over-year[10] - Gross Revenue increased by 4% year-over-year to R$4.7 billion[12] - The company's EBT was R$1.3 billion, a 5% decrease year-over-year[12] - Net Income grew by 18% year-over-year, with a diluted EPS growth of 30% CAGR[15] - The company's ROE was 24.4%, a 223 bps increase year-over-year[14] Retail Investments - Retail Net New Money amounted to R$16 billion[26] - Retail revenue increased by 9% year-over-year to R$3.577 billion[66] - Equities and Fixed Income are the main contributors in Retail revenue[69] Wholesale - Institutional, Corporate, and Issuer Services Gross Revenue reached R$3.619 billion LTM[54] - Investment Banking DCM Volume was R$34 billion[54] Capital Management - The company's BIS Ratio is 20.1%[14, 105] - The company's VaR is R$28 million, or 13 bps of Equity[107]

Company Overview - As of June 30, 2025, CareTrust REIT's real estate portfolio has grown to 393 net-leased healthcare properties across 32 states and the United Kingdom, consisting of 35,719 operating beds/units[15] - CareTrust REIT also had 22 other real estate related investments related to 142 healthcare properties across 17 states, consisting of 13,944 operating beds/units and one financing receivable related to 46 properties in one state consisting of 3,820 operating beds/units[15] - The company's total investments reached $4,760 million, encompassing 581 properties and 53,483 operating beds/units across 46 operators and 34 states plus the UK[19] Portfolio Performance - As of June 30, 2025, Skilled Nursing Facilities (SNF) constitute 47.3% of the total investment, amounting to $2,252.12 million and generating $234.715 million in rent, with a current yield of 10.4%[31] - UK Care Homes represent 18.9% of the total investment, valued at $901.593 million, producing $67.500 million in rent, with a current yield of 7.5%[31] - Multi-Service Campuses account for 10.4% of the total investment, totaling $494.236 million and yielding $47.776 million in rent, with a current yield of 9.7%[31] - Seniors Housing makes up 3.8% of the total investment, with a value of $178.997 million, generating $17.010 million in rent, with a current yield of 9.5%[31] - Total Net-Leased Assets represent 80.4% of the total investment, amounting to $3,826.946 million and producing $367.001 million in rent, with a current yield of 9.6%[31] Financial Highlights - For the three months ended June 30, 2025, rental income was $86.033 million, compared to $55.407 million for the same period in 2024[52] - Net income attributable to CareTrust REIT, Inc for the three months ended June 30, 2025, was $68.545 million, or $0.36 per basic share[52] - The company's debt structure as of July 31, 2025, includes $400 million in senior unsecured notes payable at 3.875% and $500 million in senior unsecured term loan at 4.630%[63]

Financial Performance - Ryan Specialty's total revenue for the Last Twelve Months(LTM) ending June 30, 2025, was $2.814 billion[9, 52] - The company's Organic Revenue Growth for the period ending June 30, 2025, was 9.6%[9] - Adjusted EBITDAC for the LTM ending June 30, 2025, reached $915 million, with an Adjusted EBITDAC Margin of 32.5%[54] Market Position and Growth - Ryan Specialty is the 2nd largest U S P&C wholesale broker/managing underwriter[9] - The company experienced a total revenue growth of 23.9% for the period ending June 30, 2025[9] - Ryan Specialty's revenue growth with the top 100 retail brokerage firms exceeded the company's organic revenue growth of 12.8% in 2024[36] Market Dynamics - Excess and Surplus (E&S) premiums are growing faster than the admitted market, with E&S representing 24% of the commercial market[13, 18] - Delegated authority represented 29% of E&S premiums in 2023[36] Strategic Activities - Ryan Specialty has completed 62 acquisitions since its founding[35] - Approximately $115 million of revenue was acquired thus far in 2025[37] - Wholesale Brokerage accounts for 56% of the business, Underwriting Management 31%, and Binding Authority 13%[28]

Financial Data and Key Metrics Changes - Total Recurring Contract Value (TRCV) increased by 2% sequentially, marking the third consecutive quarter of sequential growth and the highest growth rate since early 2021 [8][9] - Adjusted EBITDA margin remains strong at 30%, reflecting disciplined cost management and operational efficiency [10][11] - The company repurchased 382,000 shares, approximately 2% of outstanding stock, at an average price of $14.96 per share during the quarter [12] Business Line Data and Key Metrics Changes - The company experienced the strongest year-to-date sales since 2021, with increased win rate percentage and average win size year-over-year [9] - Retention rates improved due to the strength of the customer success organization, indicating better customer satisfaction and loyalty [10] Market Data and Key Metrics Changes - The top 400 largest healthcare systems represent the target market, which has shown signs of recovery post-pandemic but faces budget pressures [12][13] - The competitive environment remains challenging, but the company's value proposition resonates with customers [12] Company Strategy and Development Direction - The company aims to enhance its market position by focusing on deeper, human-centered connections between healthcare providers and patients [7][8] - Plans for capital allocation include continuing dividends and share repurchases while funding organic growth opportunities and potential mergers and acquisitions [12] Management's Comments on Operating Environment and Future Outlook - The new CEO emphasized the importance of understanding the unique pressures and regulations of healthcare organizations as a competitive advantage [17][18] - The company is in the early stages of developing a strategic plan, with a focus on sustainable growth and long-term margin improvement [19][20] Other Important Information - The company is actively searching for a new Chief Financial Officer, indicating a focus on strengthening the executive team [13][14] - The CEO highlighted the importance of a high-touch customer success model, which differentiates the company from competitors [18] Q&A Session Summary Question: What is the current status of the sales organization? - The sales organization is being reorganized under Jason Rao, with positive momentum reflected in the size of the pipeline and new customer acquisitions [14][15] Question: How does the company differentiate itself in the competitive environment? - The company differentiates through deep healthcare experience and a high-touch customer success model, which builds trust and accelerates value realization for clients [16][17][18] Question: Are there any material investments planned? - The CEO is excited about future value creation opportunities but is still in the early stages of assessing specific investment plans or timelines [19][20]

Financial Performance Highlights - Net income for 2Q25 was $19.4 million, a 7.7% increase quarter-over-quarter and a 151.3% increase year-over-year[7] - Adjusted net income for 2Q25 was $20.2 million, up 4.5% from the previous quarter and 131.2% compared to 2Q24[7] - Diluted EPS reached $1.01, showing a 7.7% increase from 1Q25 and a 37.1% increase from 2Q24[7] - Adjusted diluted EPS was $1.04, a 4% increase from 1Q25 and a 25.3% increase from 2Q24[7] - The company's assets totaled $5,387.6 million, representing a 68.4% increase compared to $3,198.8 million in 2Q24, but a decrease of 1% from $5,441.6 million in 1Q25[7] - Loans amounted to $3,931.4 million, a 1.4% increase from the previous quarter and a 67.5% increase from $2,347.6 million in 2Q24[7] - Deposits totaled $4,516.6 million, a decrease of 2.5% from the previous quarter but a 67.1% increase from $2,702.9 million in 2Q24[7] Profitability and Efficiency - Annualized ROAA was 1.45%, a 10 bps increase from the previous quarter and a 48 bps increase year-over-year[7] - Adjusted annualized ROAA was 1.51%, a 6 bps increase from 1Q25 and a 42 bps increase from 2Q24[7] - The efficiency ratio improved to 60.25%, a decrease of 297 bps from the previous quarter and 778 bps from 2Q24[7] - Adjusted efficiency ratio was 58.70%, a decrease of 180 bps from 1Q25 and 590 bps from 2Q24[7] - Net interest margin improved to 4.07%, a 7 bps increase from the previous quarter and a 52 bps increase year-over-year[7]

Financial Data and Key Metrics Changes - In Q1 2025, net revenue was approximately $64.2 million, a decrease of 17% year over year, driven by a 17% decrease in total orders placed and a 5% decrease in average order value [24] - Gross margin for the quarter was 40.3%, down 200 basis points compared to the prior year, although product margin improved by 100 basis points [24] - The net loss for Q1 worsened to $8 million from $5.7 million in the same period last year, with adjusted EBITDA loss at approximately $4.7 million compared to a $2.7 million loss in Q1 2024 [25][26] - Free cash flow during Q1 was $7.8 million, reflecting a $1.8 million increase year over year, and net debt was reduced to $1.5 million, a $7.2 million reduction from the previous quarter [28] Business Line Data and Key Metrics Changes - The Special Occasion and Bridesmaids categories continued to show positive momentum, driving healthy year-over-year net sales growth, while casualwear and footwear remained under pressure [6][10] - Inventory management resulted in a 4% year-over-year inventory reduction, with product margins increasing sequentially for the second consecutive quarter [8][9] - The Shoes and Separates businesses were a drag on overall results, accounting for most of the year-over-year decline in net sales [10] Market Data and Key Metrics Changes - Q1 revenue in Wholesale had triple-digit year-over-year growth, driven by continued growth among major partners and strong momentum in specialty retail [10] - Active customers increased quarter over quarter despite a year-over-year decline, reflecting the success of recent brand efforts [16] Company Strategy and Development Direction - The company is focused on strengthening its financial foundation, optimizing its business, and broadening its customer base through strategic initiatives [7][31] - A key focus area is SKU management, shifting towards deeper buys on a narrower, more curated SKU set supported by data insights [13] - The company is committed to maintaining positive cash flow and investing in long-term objectives to support a return to growth [31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macroeconomic environment and potential unstable consumer sentiment due to international trade policies and tariffs [13][31] - The company expects to generate positive adjusted EBITDA in Q2 2025 and is committed to strengthening its liquidity position [30] Other Important Information - The company executed a fourth amendment to its credit agreement with Bank of America, which suspended the measurement of certain financial covenants for Q1 [28] - The company is actively evaluating its sourcing plans to diversify its supply base and reduce reliance on China [14][15] Q&A Session Summary Question: No questions were asked during the Q&A session - There were no questions from participants during the Q&A session, leading to the conclusion of the conference call [34]

Financial Performance - The company's estimated combined risk-based capital (RBC) ratio is between 420% and 440%[9, 30] - Holding company liquid assets stand at $1.0 billion[9, 29, 30] - Statutory combined total adjusted capital (TAC) is $5.5 billion[9] - Normalized statutory earnings are $0.3 billion[9] - Adjusted earnings, less notable items, were $245 million, $15 million below expectations due to lower alternative investment income yield of 1.4%[9] Share Repurchases - The company repurchased $59 million of common stock in 1Q 2025[9, 29] - An additional $26 million of common stock was repurchased through May 6, 2025[9] Segment Performance - Annuities adjusted earnings, less notable items, were $324 million in 1Q 2025[12] - Life Insurance adjusted earnings, less notable items, were $9 million in 1Q 2025[14] - Run-off segment had adjusted earnings (loss), less notable items, of $(64) million in 1Q 2025[19] - Corporate & Other segment had adjusted earnings (loss), less notable items, of $(24) million in 1Q 2025[23] Investment Portfolio - Total investments amount to $124 billion[40] - Fixed maturity securities (FMS) total $87 billion, with 97% being investment grade[40]

Financial Performance - Total revenue for 1Q25 was $1497 million, a 40% year-over-year increase[15] - Adjusted EBITDA for 1Q25 was $98 million, a 25% year-over-year increase[15] - Adjusted EBITDA margin was 66% in 1Q25, a decrease of 10 basis points year-over-year[15] Operating Metrics - Admissions increased by 76% year-over-year, totaling 41389[15] - Adjusted Admissions increased by 27% year-over-year, totaling 84536[15] - Net Patient Service Revenue per Adjusted Admission increased by 12% year-over-year, reaching $17402[15] Capital Structure - The company has $495 million in ABL Capacity and $295 million in total cash, resulting in $790 million available liquidity[32] - Net leverage is 26x and lease-adjusted net leverage is 30x[32] 2025 Full Year Guidance - Total revenue is projected to be between $6200 million and $6450 million[38] - Adjusted EBITDA is projected to be between $575 million and $615 million[38]

Group 1 - The conference call is focused on the First Quarter Earnings for 2025, with an emphasis on non-GAAP financial information to assist investors in reconciling financial data [3] - The financial results are presented in U.S. dollars, which is the company's functional currency [4] - The call may include forward-looking statements based on the company's expectations and market trends, which are subject to uncertainties [4][5] Group 2 - The company encourages reviewing detailed financial information published with the Brazilian Comissão de Valores Mobiliários (CVM) [5]

Financial Performance - First quarter sales increased by 2% year-over-year, from $800.5 million to $814.3 million[18, 80] - Organic sales decreased by 1%[19] - Adjusted EBITDA margin decreased by 50 bps, from 26% to 25.5%[18] - Adjusted EPS decreased by 7%, from $1.88 to $1.75[18] - Free cash flow decreased by 33%, from $136.6 million to $91.4 million[18, 82] Segment Results - Health & Science Technologies (HST) sales increased by 10%, with organic sales down by 1%[27] - Fluid & Metering Technologies (FMT) sales decreased by 7%, with organic sales down by 4%[33] - Fire & Safety/Diversified Products (FSDP) sales increased by 4%, with organic sales up by 5%[42] Guidance - The company expects organic revenue to increase by 1% to 3% for the full year 2025[49] - The company expects adjusted EBITDA to be 27.5% to 28.0% for the full year 2025[49] - The company expects adjusted EPS to be $8.10 to $8.45 for the full year 2025[49] Tariff Impact - The total annualized tariff impact is estimated to be approximately $100 million[54]